$0.13
3.86% yesterday
Nasdaq, May 20, 09:50 pm CET
ISIN
US71678J1007
Symbol
PTPI
Sector
Industry

Petros Pharmaceuticals Inc Stock price

$0.12
-0.93 88.19% 1M
-6.06 97.99% 6M
-9.72 98.74% YTD
-15.50 99.21% 1Y
-190.13 99.93% 3Y
-1,499.88 99.99% 5Y
-36,399.88 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 6.13%
ISIN
US71678J1007
Symbol
PTPI
Sector
Industry

Key metrics

Market capitalization $3.86m
Enterprise Value $-5.07m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 1.61
EV/Sales (TTM) EV/Sales -1.36
P/S ratio (TTM) P/S ratio 1.04
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $3.72m
EBIT (operating result TTM) EBIT $-7.83m
Free Cash Flow (TTM) Free Cash Flow $-3.15m
Cash position $8.93m
EPS (TTM) EPS $-57.59
P/S forward 0.57
EV/Sales forward 0.81
Short interest 24.00%
Show more

Is Petros Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

Buy
100%

Financial data from Petros Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.72 3.72
47% 47%
100%
- Direct Costs 2.99 2.99
48% 48%
80%
0.73 0.73
41% 41%
20%
- Selling and Administrative Expenses 6.36 6.36
9% 9%
171%
- Research and Development Expense - -
-
-
-5.64 -5.64
11% 11%
-152%
- Depreciation and Amortization 2.19 2.19
37% 37%
59%
EBIT (Operating Income) EBIT -7.83 -7.83
20% 20%
-210%
Net Profit -14 -14
14% 14%
-388%

In millions USD.

Don't miss a Thing! We will send you all news about Petros Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Petros Pharmaceuticals Inc Stock News

Neutral
Accesswire
about 15 hours ago
With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, toda...
Neutral
Accesswire
15 days ago
Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today an...
Neutral
Accesswire
20 days ago
Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (MAHA) initiative NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication t...
More Petros Pharmaceuticals Inc News

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office United States
CEO John Shulman
Employees 18
Website www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today